5 Questions on Soft-Tissue and Bone Sarcomas

Question 1:

Answer and Question 2 on Next Page »

The correct answer is: C. 12,390. By comparison, it is estimated that 3,260 bone sarcomas will be diagnosed in 2017.

Question 2:

Answer and Question 3 on Next Page »

The correct answer is: A. Had longer overall survival from the time of diagnosis. Similar to the reported literature, the 20 sarcoma patients in this series with brain metastases lived longer and presented with brain metastases late in their disease course. Routine screening for brain metastases in sarcoma patients is not implemented, yet the increasing incidence of sarcoma brain metastases “mandates special attention since earlier detection may affect treatment strategies,” the investigators wrote, and could have a “potential impact on management of brain metastasis in the future.” The findings were presented at the 2016 American Society of Clinical Oncology Annual Meeting.

Question 3:

Answer and Question 4 on Next Page »

The correct answer is: A. Chondrosarcoma and synovial cell sarcoma. Median progression-free survival observed in the trial was 4.5 months for chondrosarcoma and 6.8 months for synovial sarcoma. For liposarcoma, median progression-free survival was 4.3 months and for leiomyosarcoma, 3.7 months.

Question 4:

Answer and Question 5 on Next Page »

The correct answer is: C. Pomalidomide. This study “provides formative evidence that pomalidomide can address key unmet clinical needs for people with Kaposi sarcoma,” the authors concluded. Oral pomalidomide may be especially useful in combination with cytotoxic chemotherapy for patients in resource-limited regions, such as sub-Saharan Africa.

Question 5:

Answer on Next Page »

The correct answer is: D. All of the above. Certain family cancer syndromes such as retinoblastoma, von Recklinghausen disease, Gardner syndrome, Werner syndrome, Li-Fraumeni syndrome, and others are also a risk factor for soft-tissue sarcoma. Lifestyle factors such as smoking, diet, and exercise are not linked to the risk of soft-tissue sarcoma.